Discover how ledipasvir and sofosbuvir are achieving cure rates above 95% for hepatitis C in patients coinfected with HIV, transforming treatment outcomes.
Explore how elvitegravir transformed HIV treatment through its unique mechanism as an integrase inhibitor, with insights into its clinical performance and molecular trade-offs.
Exploring ibalizumab's breakthrough in treating multidrug-resistant HIV across disease severity levels through the TMB-311 expanded access trial.
Exploring the mechanisms of viral persistence and how some viruses establish long-term infections in human hosts.